Breadcrumb

null Peter Lakatos, MD, PhD

Investigator, RI-MUHC, Montreal General Hospital site

Infectious Diseases and Immunity in Global Health Program

Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Gastroenterology, MUHC

 

Keywords

IBD • epidemiology • outcome research • biomarkers • prediction • advanced therapies

Research Focus

My research focuses on quality of care, epidemiology, biomarkers and outcomes research in IBD, including the mapping of epidemiology, clinical characteristics, treatment outcomes and prediction of disease outcomes of IBD in Europe, and now Quebec. More recently, one of my research focus is the assessment of clinical and economic impact of new and old biologicals in IBD, access and use of biosimilars (care affordability), efficacy and safety of new therapeutics, assessment of treatment outcomes in administrative databases (RAMQ in Quebec, NEAK in Hungary) harmonization of care pathways and quality of care indicators. In addition, our group assesses the accuracy of objective disease assessment (e.g. endoscopic/histological scores) in predicting disease outcomes. As a new research theme, we started organoid (3D gut-on-chip) research in collaboration to better characterize the chronic inflammatory pathways potentially leading to new treatment targets.

Selected Publications

Click on Pubmed to see my current publications list

  • Hracs, Lindsay et al. “Global evolution of inflammatory bowel disease across epidemiologic stages.” Nature vol. 642,8067 (2025): 458-466. doi:10.1038/s41586-025-08940-0. PMID: 40307548.

  • Angyal, Dorottya et al. “Inflammatory bowel diseases in the elderly population: epidemiology, long-term disease course, surgery rates, and biological use-data from the Veszprem county cohort between 1977 and 2020.” Journal of Crohn's & colitis vol. 19,1 (2025): jjaf003. doi:10.1093/ecco-jcc/jjaf003. PMID: 39758021.

  • Burisch, Johan et al. “The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission.” The lancet. Gastroenterology & hepatology vol. 8,5 (2023): 458-492. doi:10.1016/S2468-1253(23)00003-1. PMID: 36871566.

  • Vermeire, Severine et al. “Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.” The lancet. Gastroenterology & hepatology vol. 7,1 (2022): 28-37. doi:10.1016/S2468-1253(21)00295-8. PMID: 34798037.

  • Gecse, Krisztina B et al. “Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.” Journal of Crohn's & colitis vol. 10,2 (2016): 133-40. doi:10.1093/ecco-jcc/jjv220. PMID: 26661272.